TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00668330
Drug: placebo ibandronate+alfacalcidol+calcium
Normalized name: alfacalcidol
DrugBank: Alfacalcidol (DB01436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo ibandronate monthly plus daily alfacalcidol(1ug)500mg calcium
Study: NCT02533349
Drug: Motilitone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30mg, 1 tablet, 3 times a day
Study: NCT02533349
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30mg, 1 tablet, 3 times a day
Study: NCT02151630
Drug: Pyruvic acid
Normalized name: Pyruvic acid
DrugBank: Pyruvic acid (DB00119)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00460564
Drug: GSK1358820
Approvals — FDA: no, EMA: no, PMDA: no
Description: botulinum toxin type A
Study: NCT00460564
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01245803
Drug: placebo control
Approvals — FDA: no, EMA: no, PMDA: no
Description: sugar pill is given 18-24hr and 4-6hr before PCI as control
Study: NCT00018057
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Randomized assignment.
Study: NCT02218489
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: The vehicle control has the same composition as KPI-121 0.25% ophthalmic suspension except it does not contain loteprednol etabonate. The vehicle is essentially isotonic and is buffered to maintain pH 5.0 - 7.0. It is a sterile, aqueous solution supplied in the same white, low-density polyethylene plastic dropper bottle with the same white, controlled-drop polyethylene tip and white polypropylene closure as KPI-121 0.25% ophthalmic suspension.
Study: NCT03781713
Drug: Drug interaction risk D or X
Normalized name: alpha-D-galactosidase enzyme Oral Capsule [Gas-X Prevention]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention in the therapeutic plan in order to avoid adverse drug reactions.
Study: NCT03781713
Drug: Antimicrobial stewardship
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimization of anticrobial therapy based on Gram stain, MALDI TOF, MIC and antimicrobial susceptibility
Study: NCT04252287
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo capsules orally once daily.
Study: NCT02396537
Drug: 0.9% Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intranasally prior to Midazolam administration.
Study: NCT00214032
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo 3 capsules daily
Study: NCT03153111
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: film-coated tablet (identical to the macitentan tablet); oral use
Study: NCT03891524
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo matching to JNJ-70033093, orally.
Study: NCT02571283
Drug: Cocktail
Normalized name: Cocktail
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as a single dose injection.
Study: NCT01427192
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet (Mannitol) similar to acetazolamide
Study: NCT03298763
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be made up of the same material used to cryopreserve the ATIMP (MSCTRAIL) but will not include the active product
Study: NCT00003423
Drug: mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003423
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003423
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03067103
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 2mL of saline solution in peritonsillar fossa prior to surgery
Study: NCT02254096
Drug: BIRT 1696 BS
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02254096
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00670696
Drug: Rapydan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anaesthetic plaster
Study: NCT04651556
Drug: paracetamol & ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: parenteral analgesics
Study: NCT03384654
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participant will receive doxorubicin 60 mg/m\^2 in cohort 2.
Study: NCT02046798
Drug: ASP3652
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT02959177
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT03384654
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participant will receive cyclophosphamide 1 gram per meter square (g/m\^2) once in cohort 2.
Study: NCT03384654
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participant will receive methotrexate 5 g/m\^2 intravenously (IV) in cohort 2.
Study: NCT00615173
Drug: cyclophosphamide or azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction phase: CTX 0.75g/m2 monthly Maintenance phase: AZA 2mg/kg/d.
Study: NCT01163747
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A stable dose of between 7.5 and 25 mg/week, oral or parenteral.
Study: NCT00591409
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: After induction of anesthesia an intubation dose of NMBA was administered IV: either 0.9 mg/kg rocuronium or 0.1 mg/kg vecuronium.~Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.04 mg/kg vecuronium IV could be administered if necessary.~At reappearance of T2 the randomized single dose of placebo IV was administered
Study: NCT01644110
Drug: INCB018424/CC-4047
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 1: For patients (1-41) the starting dose of ruxolitinib in this trial is 10 mg twice daily po; pomalidomide will be administered at a permanent dose of 0.5 mg po once daily.~Cohort 2: For patients (42-90) the starting dose of ruxolitinib in this trial is 10 mg twice daily po; the starting dose of pomalidomide is 0.5 mg po once daily.
Study: NCT02036255
Drug: Taurolidine Heparin
Normalized name: heparin / taurolidine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02392572
Drug: Akt/ERK Inhibitor ONC201
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT01870648
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible children will receive one dose of an oral disintegrating Placebo (sugar pill) tablet. Subsequent therapy will be in accordance with World Health Organization guidelines as dictated by the child's hydration status.
Study: NCT02974725
Drug: LTT462
Approvals — FDA: no, EMA: no, PMDA: no
Description: LTT462 will be supplied as hard gelatin capsule for oral use.
Study: NCT01970722
Drug: Pegylated Liposomal Doxorubicin Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IP or IV
Study: NCT00874497
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 104 weeks (2 years)
Study: NCT02689466
Drug: [18F]FP-TZTP
Approvals — FDA: no, EMA: no, PMDA: no
Description: radioligand
Study: NCT00330681
Drug: MCI-186
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
Study: NCT04620369
Drug: Placebo Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instill isotonic nasal saline intranasally
Study: NCT00067093
Drug: SanOrg34006
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00067093
Drug: LMW heparin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00067093
Drug: Vitamin K antagonist (VKA)
Normalized name: Vitamin K antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00134147
Drug: Inhaled Insulin
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03540758
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-diabetic participants will receive placebo and undergo the pancreatic clamp study.~T2D participants will have their blood sugar levels normalized, and will then receive a taste-matched placebo for diazoxide before undergoing the pancreatic clamp study.
Study: NCT00142038
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00087555
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo one of two doses matching active treatment by volume for 8 weeks.
Study: NCT01212484
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The trial will be divided into two consecutive, but independent parts. Phase 1, will address the safety and tolerability of carbidopa in patients with FD using an open-label dose titration phase followed by 4-weeks of open-label treatment. Phase 2, will address the efficacy of carbidopa for the treatment of nausea in patients with FD using a randomized, placebo controlled, double blind, 4-week cross over design.
Study: NCT01290783
Drug: Irintoecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Irinotecan, 180 mg/m2 IV, over 90 minutes, day 1 (in patients \> 75 years of age, the irinotecan dose in must be reduced to 150 mg/m2).~* Leucovorin, 400 mg/m2, or levoleucovorin, 200 mg/m2, IV over 90 minutes with irinotecan.~* 5-FU, 400 mg/m2 IV bolus day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion.~* Repeat every two weeks.~* 8 months of treatment.
Study: NCT03816891
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: solution for injection
Study: NCT01246219
Drug: GH treatment (Genotropin)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 years treatment with GH
Study: NCT01246219
Drug: 1 year treatment with placebo followed by optional 3 years of GH treatment
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 year treatment with placebo followed by optional 3 years of GH treatment
Study: NCT03688022
Drug: PPI
Normalized name: PPIase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitor
Study: NCT02218775
Drug: LY2456302
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mood and Anxiety Disorders
Study: NCT02778906
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of the comparator s.c. weekly in comparable to verum
Study: NCT00613288
Drug: Testosterone (Testogel), GnRH analog (Leuprorelide) and Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The trial is a double blinded, randomised cross-over study of 4 x 2 days with an interval of 1 month in between. 12 healthy young male participants will receive the GnRH-agonist leuprorelide 7,5 mg s.c. 3 weeks before examination on 3 occasions, and a fourth day without intervention.~The four days will include treatment on the examination day, Day 1 with:~1. Placebo (hypogonadism after leuprorelide injection)~2. Testosterone gel 50 mg applicated in the morning at 06.00 am (physiologic substitution - after leuprorelide injection).~3. Testosterone gel 150 mg applicated in the morning at 06.00 am (supra-physiologic substitution - after leuprorelide injection).~4. No treatment.
Study: NCT01149876
Drug: Tretinoin cream 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thin layer of tretinoin applied to face.
Study: NCT01438515
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mg po twice daily x 7 days
Study: NCT02220777
Drug: ASP8477
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT02220777
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT01729923
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT01729923
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT02057263
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 4 doses of placebo during the course of the study.
Study: NCT03020056
Drug: Phacolin eye drops
Normalized name: Hycolin
Approvals — FDA: no, EMA: no, PMDA: no
Description: After enrollment, the participants will be provided antioxidant eye drops, Phacolin (Zhongshan ophthalmic center, China) for free.The eye drops will be administered 4 times per day for 1 year.Then either phacoemulsification or manual small incision cataract surgery will be performed.
Study: NCT03374475
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will receive matching placebo capsule during lead in period, treatment period and withdrawal period.
Study: NCT02558270
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00744328
Drug: Transdermal Estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol patch ranging in dose from 50 to 200 mcg/day
Study: NCT02252614
Drug: naproxen sodium codein
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pain intensity, contramal consumption
Study: NCT02252614
Drug: paracetamol codein
Normalized name: codeine and paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain intensity, contramal consumption
Study: NCT02252614
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain intensity, contramal consumption
Study: NCT00818363
Drug: SABER-Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable Solution; 5.0 mL SABER-Placebo/Once
Study: NCT00700063
Drug: PEP005 Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.005%, two days treatment
Study: NCT00700063
Drug: PEP005 Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.01%, two days treatment
Study: NCT02186080
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00700063
Drug: PEP005 Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.015%, two days treatment
Study: NCT01536041
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match ONO-6950 tablets or leukotriene receptor antagonist (LTRA) tablets dosed in a similar manner
Study: NCT00700063
Drug: PEP005 Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.005%, three days treatment
Study: NCT00700063
Drug: PEP005 Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.01%, three days treatment
Study: NCT00700063
Drug: Vehicle gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: three days treatment
Study: NCT03011905
Drug: EtoriCoxib
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premedication and first 2 postoperative days.
Study: NCT02269917
Drug: D/C/F/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily single-tablet regimen containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg.
Study: NCT02269917
Drug: Boosted Protease Inhibitor (bPI)
Normalized name: Protease inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boosted protease inhibitor (limited to darunavir \[DRV\] or atazanavir with low-dose ritonavir \[rtv\] or cobicistat \[COBI\], or lopinavir with rtv) as per current treatment regimen.
Study: NCT02269917
Drug: FTC/TDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF).
Study: NCT00613132
Drug: Gleevec, RAD001, and Hydroxyurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose of Gleevec will be 400 mg in 1st cohort \& will be increased to 600 mg po/day \& then to 400 mg bid in successive cohorts. Prescribed dose should be administered orally, w large glass of water. Pts should not eat large or high fat meal within 1 hour before or after gleevec dosing. Doses of 600 mg or less should be administered once daily, whereas doses greater than 600 mg should be administered as equal doses twice day. It is recommended that pts take their prescribed Gleevec at same time that they take their prescribed RAD001 \& hydroxyurea, however, 30-60 minute interval between agents is acceptable if required for practical or other compliance issues.
Study: NCT03459612
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT00097669
Drug: Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug) or placebo
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: multivitamin
Study: NCT00303563
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: po qd
Study: NCT01180790
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powder in capsule once daily
Study: NCT02183077
Drug: Meloxicam gel
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02183077
Drug: Meloxicam tablet
Normalized name: Meloxicam Tablets
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00692640
Drug: XL147 (SAR245408)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelatin capsules supplied in 25-mg and 100-mg strengths; daily dosing for 21 days/7 days off
Study: NCT01393613
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, once daily, for six weeks
Study: NCT00330681
Drug: Placebo of MCI-186
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two ampoules of placebo injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
Study: NCT02598934
Drug: Ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive oral ibandronate, 150 mg once weekly, for approximately 6 months.
Study: NCT03952598
Drug: HP 13C Pyruvate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast agent used with magnetic resonance spectroscopic imaging (MRSI)
Study: NCT03955354
Drug: SHR1210
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
Study: NCT00344253
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00791297
Drug: CDB-2914
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contraceptive Vaginal Rings delivering a daily dose of 1500 or 2500 μg of CDB-2914
Study: NCT04513275
Drug: non-medicine intervention
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: rating by MCCB only one time
Study: NCT00004847
Drug: ([18F]-DOPA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: is L 3, 4 dihydroxyphenylalanine (L-DOPA) labeled with the radioactive isotope 18F. In general, PPGLs belong to the group of neuroendocrine tumors. This heterogeneous group of tumors takes up amino acids, transforms them into biogenic amines (dopamine and serotonin) by decarboxylation and stores the amines in vesicles. L DOPA is a precursor of catecholamines (dopamine, norepinephrine and epinephrine). Epinephrine conversion to dopamine is catalyzed by the aromatic amino acid decarboxylase. According to previous and current studies, \[18F\]-DOPA PET is highly sensitive and specific for detection of PHEO/PGL67-69. However, there are only a few reports in the literature using \[18F\]-DOPA as a PET agent and particularly for patients with metastatic PPGLs. PET imaging will be done together with either a CT, an MRI or both modalities.
Study: NCT00004847
Drug: ([18F]-6F-DA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: is an imaging agent developed at the NIH, that may improve specificity and sensitivity in the localization of PPGLs. \[18F\]-6F-DA enters cells via the membrane norepinephrine transporter. Once inside cells, \[18F\]-6F-DA is translocated via the vesicular monoamine transporter into storage vesicles, where the radioactivity is concentrated. After injection of \[18F\]-6F-DA, the much faster disappearance of \[18F\]-6F-DA-derived radioactivity from the bloodstream and non-neuronal cells than from chromaffin cells should enable rapid visualization of PPGLs by PET scanning.
Study: NCT01004029
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly intramuscular injections of 1 mL vehicle inert oil until 36 weeks, 6 days of gestation or delivery, whichever occurs first.
Study: NCT02383238
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral for 6 weeks
Study: NCT04804059
Drug: [14C]-APX001 Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total dose containing NMT 3.1 MBq (84.0 µCi) 14C
Study: NCT04804059
Drug: [14C]-APX001 Solution for Infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total dose containing NMT 3.4 MBq (93.0 µCi) 14C
Study: NCT04278495
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02517528
Drug: ABT-333
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT02326350
Drug: Lactose powder
Normalized name: Lactose Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02311777
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be given orally during preoperative period
Study: NCT00386308
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01941992
Drug: SAMITAL®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01941992
Drug: Placebo sachets
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00590070
Drug: adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine (80 mcg as fast bolus followed by 2 mg given in 33cc of saline in 2 minutes as slow bolus)
Study: NCT00590070
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 33 cc of heparinized saline given in 2 minutes as slow bolus
Study: NCT00663117
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo